Princeton, NJ — Evotec AG, a global drug discovery alliance and development partnership company headquartered in Hamburg, Germany, celebrated the opening of its U.S. headquarters and expanded facility in Princeton, New Jersey.
Werner Lanthaler, Chief Executive Officer of Evotec AG and Ryan Brady, the company’s Executive Vice President Business Development and Head of U.S. Operations were joined by Michele Brown, President and CEO of Choose New Jersey, Inc. and Debbie Hart, President and CEO of BioNJ to cut the ribbon for the new U.S. headquarters. Invited guests representing the biopharmaceutical and business community also were on hand to celebrate the headquarters opening and Princeton facility expansion.
“Princeton is an ideal location for our U.S. headquarters based on its proximity to many of the world’s leading biopharmaceutical and Pharma companies and universities, as well as its experienced talent pool that has knowledge and expertise in drug discovery,” said Dr. Werner Lanthaler. “Our Princeton location puts us in easy reach of many our alliance and development partners and gives us the opportunity to cultivate new partnerships in the U.S.”
Evotec has been involved in more than 250 partnerships since its inception in 1993 and has delivered more than 30 pre-clinical candidates and 20 clinical candidates both in partnerships and within its own proprietary drug discovery efforts. Evotec’s partners consist of the Top 20 pharmaceutical companies, many biotechnology and mid-sized pharmaceutical companies, academic institutions, foundations and not-for-profit organizations. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in multiple areas including neuroscience, pain, metabolic diseases, oncology, inflammation and infectious diseases.
The company currently has more than 1,200 employees worldwide in its headquarters in Hamburg, Germany and in additional operating sites in Abingdon and Manchester, UK; Göttingen and Munich, Germany; Toulouse, France; and in the United States in Branford, CT and Watertown, MA.
Evotec established its Princeton office in 2015 and currently employs a team of more than 20 employees. The 20,000-square-foot expanded facility accommodates additional laboratory and office space for its growing operations in New Jersey.
“We are excited that Evotec chose New Jersey for its U.S. headquarters and look forward to working with the company as it continues to expand its operations in Princeton,” said Ms. Brown. “The company’s focus on innovative drug discovery has made it a welcome addition to our State’s biopharmaceutical ecosystem.”
Choose New Jersey, a privately-funded non-profit organization charged with encouraging and nurturing economic growth throughout the State, and BioNJ, the New Jersey affiliate of BIO International provided assistance to Evotec to ensure the successful establishment of its U.S. headquarters and facility expansion in New Jersey.
About Evotec AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com.
About Choose New Jersey
Choose New Jersey, Inc. is a privately funded 501(c)(3) corporation charged with encouraging and nurturing economic growth throughout New Jersey with a focus on its urban centers. Through marketing, business attraction and lead generation activities, Choose New Jersey markets New Jersey as a premier business location to both domestic and international businesses. Choose New Jersey is a member of the Partnership for Action (PFA), which is led by Lt. Governor Kim Guadagno and includes the New Jersey Business Action Center, the New Jersey Economic Development Authority and the Office of the Secretary of Higher Education. For more information, visit www.choosenj.com.